CDA Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about CDA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia

Congenital Dyserythropoietic Anemia (CDA)
Institute of Hematology & Blood Diseases Hospital, China2 enrolled1 locationNCT07471516
Recruiting

Integrative Diagnosis for SCD and Other RADs

Sickle Cell DiseaseThalassaemiaStomatocytosis+6 more
Hospital Universitari Vall d'Hebron Research Institute200 enrolled9 locationsNCT07206095
Recruiting

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

Metabolic DiseaseAMPD3, OMIM*102772, AMP Deaminase DeficiencyAK1, OMIM *103000, Adenylate Kinase Deficiency+25 more
National Human Genome Research Institute (NHGRI)999 enrolled1 locationNCT06092346
Recruiting

The Congenital Dyserythropoietic Anemia Registry (CDAR)

Congenital Dyserythropoietic Anemia (CDA)
Children's Hospital Medical Center, Cincinnati10,000 enrolled1 locationNCT02964494
Recruiting

A New Digital Communication Tool Between Dentist and Orthodontist to Improve Dental Prevention

Reduction in DMFT Index and Plaque Index in Patients at the Treatment Completion, an Average of 4 YearsDMFT Index, ICDAS Score, Dental Plaque Index, Communication, Prevention, Dentist, Orthodontist
CHU de Reims30 enrolled1 locationNCT06517238
Recruiting

RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)

Sickle Cell DiseaseIron Metabolism DisordersThalassemia+6 more
Hospital Universitari Vall d'Hebron Research Institute32,564 enrolled1 locationNCT06213402